Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial. - Wikidata - awgldk - TriplyDB

Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.

Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.

http://www.wikidata.org/entity/Q35895422

about

Indoxyl Sulfate-Review of Toxicity and Therapeutic Strategies The microbiota and chronic kidney diseases: a double-edged sword The systemic nature of CKD.Gut microbiome and kidney disease: a bidirectional relationship.Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.Beta-Glucans Supplementation Associates with Reduction in P-Cresyl Sulfate Levels and Improved Endothelial Vascular Reactivity in Healthy Individuals p-Cresyl Sulfate.Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies.Gut microbiome in chronic kidney disease: challenges and opportunities.Intestinal Microbiota in Type 2 Diabetes and Chronic Kidney Disease.Prebiotics, Prosynbiotics and Synbiotics: Can They Reduce Plasma Oxidative Stress Parameters? A Systematic Review.Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients.Intestinal metabolites, chronic kidney disease and renal transplantation: Enigma Variations?Protein-controlled versus restricted protein versus low protein diets in managing patients with non-dialysis chronic kidney disease: a single centre experience in Australia Effect of Synbiotic Therapy on Gut-Derived Uremic Toxins and the Intestinal Microbiome in Patients with CKD.Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.Short-chain fatty acids: a link between prebiotics and microbiota in chronic kidney disease.Long term variation of serum levels of uremic toxins in patients treated by post-dilution high volume on-line hemodiafiltration in comparison to standard low-flux bicarbonate dialysis: results from the REDERT study.Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.Beyond Sodium, Phosphate and Potassium: Potential Dietary Interventions in Kidney Disease.Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.The Role of Gut Microbiota and Diet on Uremic Retention Solutes Production in the Context of Chronic Kidney Disease.Gut Microbiome in Chronic Kidney Disease.Circulating Bacterial Fragments as Cardiovascular Risk Factors in CKD.Strategies to decrease oxidative stress biomarker levels in human medical conditions: A meta-analysis on 8-iso-prostaglandin F2α.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics.Probiotics, prebiotics and synbiotics for chronic kidney disease: protocol for a systematic review and meta-analysis The Gut-Kidney Axis: Putative Interconnections Between Gastrointestinal and Renal Disorders Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome Gut Microbiota and Cardiovascular Uremic Toxicities Biotic Supplements for Renal Patients: A Systematic Review and Meta-Analysis

P2860

Q28075033-EA3DE6C2-B00F-4631-84A1-55CB16941C28 Q28078306-44025E6A-ADDC-4208-96AB-3C126B344B92 Q30234695-60BC7F46-5ECD-4717-A9DF-77D0814F94B3 Q33586234-3B2AB715-BB11-4E3E-985A-5D750FB6184E Q33749467-DDB78F2C-1B09-43F6-90D2-F437B72A9D6F Q37596259-DA5B9876-DF3C-4094-B1C4-1AB1EF200A38 Q37672982-FDEFD801-6B63-4666-8A67-329823C0CC86 Q38636372-2D84EA35-795C-4593-8BF7-EEF06CDE1F08 Q38836354-D8FD3D15-8B88-4B3F-AF36-85D15A805C41 Q38921854-BDC5A4EF-AF91-4633-9CBE-8BDA5BFCE4E5 Q39065306-AAC8DCE4-8C66-4F89-BCE4-1F1700C82531 Q40051571-1C80B611-D768-461A-8533-7D0C1F9C2511 Q40749194-DF171E8C-32A5-4A43-A8BD-FAE2ED8FDDA7 Q42395408-5EB55050-1C7A-431A-8DCF-C0F0969D6915 Q42551130-35C4769D-2629-4E13-85E8-CCA449A8D319 Q42706652-D701CCB0-4CD5-4759-B719-0FC28E7DE2DB Q47216784-CFDACD76-8AE2-4851-9BEB-A70617B02FF0 Q47899492-B8C37E34-8457-4913-A00A-FE80DC25E21E Q48366548-B9A6E1F0-6931-473D-A360-9CECC663227C Q50108575-F45BDB35-1EAA-4061-95F4-79E214E6DF06 Q51121348-158BE955-5D2E-4152-B559-8D99270164A0 Q51732046-DE741BC8-448E-4CA0-AEE6-7203A1A86BC3 Q52589945-17C2C694-68E6-40A1-8F75-F64B6C3DBF1E Q52680146-8B6EB3E4-82F1-4E9A-A823-1BF6AF1888A8 Q54233821-1FB32C2E-5028-4A35-A4E2-9950555B74B6 Q55279804-8C9D3A7A-BA79-49B3-A217-5DA3CC5B8F5D Q55476982-B74F60D9-A4B5-4967-853C-0D902EFE25D3 Q55514036-5A055F3F-3E2F-495D-A9C7-5D6E528DF5C2 Q56517232-6DFCD292-55A2-4C2C-8486-FC12EA5C5835 Q57072601-4E5F01E8-9BB7-46B4-876A-8D3A2C123975 Q57117487-E133E6F9-FF1F-4B7C-94B6-973A1BF08141 Q57176511-C7F92C78-E6B4-4A4D-9061-CE41EDC960D7 Q58764123-FA0E6183-8305-41E5-8DC5-CCAAC000D7EF

P2860

Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.

http://www.wikidata.org/entity/Q35895422

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Synbiotics Easing Renal Failur ...... (SYNERGY): A Randomized Trial.

@ast

Synbiotics Easing Renal Failur ...... (SYNERGY): A Randomized Trial.

@en

type

label

Synbiotics Easing Renal Failur ...... (SYNERGY): A Randomized Trial.

@ast

Synbiotics Easing Renal Failur ...... (SYNERGY): A Randomized Trial.

@en

prefLabel

Synbiotics Easing Renal Failur ...... (SYNERGY): A Randomized Trial.

@ast

Synbiotics Easing Renal Failur ...... (SYNERGY): A Randomized Trial.

@en

P1433

Q35895422-2342CE84-1F3F-4C0B-9587-758F0750DD70

P1476

Q35895422-6901F719-A894-46B7-AC32-17F34F53E741

P2093

Q35895422-4AF04E97-E90E-4681-9243-032828F52EBA

Q35895422-8E929B22-D376-4C41-B262-47B089F650AE

Q35895422-D0538E24-72DB-4696-806B-4714C194FE19

Q35895422-EF56853E-570B-4652-9A04-A13E865DB820

Q35895422-FFE74C99-142E-4E3B-B1F4-33DA9E0661A4

P2860

Q35895422-1BC1BBF6-E155-4680-A684-CA4179C3AB28

Q35895422-33080BE5-7DFB-4431-A595-1676A52980E7

Q35895422-3D537CA0-D575-4B4F-8C12-FF54D5FA3647

Q35895422-441429EC-1714-4B00-97E1-D3D04A26CBE3

Q35895422-475569B7-B8D7-4D0E-A9FC-6921403CAE45

Q35895422-515C4326-0B45-4DB9-BB52-DE8E67A76BD2

Q35895422-565DA91F-8DEE-4504-8FFE-E6E6ED00EDCB

Q35895422-72CE2D7A-65C3-4EC6-A1A4-A65637DA251E

Q35895422-7AE3F92D-6CA5-4E4C-BB84-C2DFDA8453FE

Q35895422-7F44E795-DB78-4E16-AAC2-603713A7D1A6

P304

Q35895422-B8FDAB73-5ADD-42AA-9DC9-116D8E7C7851

P31

Q35895422-F438D84F-3D7C-4EE0-818F-0C5A72DA3FA3

P356

Q35895422-75BB4EAF-75F8-4709-95FA-AFDA27724EF9

P433

Q35895422-3B2C69A9-E771-40ED-B272-8B764982FA45

P478

Q35895422-03263489-D14B-497B-85E1-4224DE82A2AE

P50

Q35895422-20B628AD-84A3-4D1D-9CB4-650380C3C144

Q35895422-3C49E1D2-A5FB-4A2E-A8B6-18C754317B27

Q35895422-A52E2B81-7F8D-4155-A8EB-C9AECB42C0D3

Q35895422-A9E64BE1-C658-4384-A414-9C96058AE14C

Q35895422-CD25D019-1815-465E-9055-17128D7B0D39

P577

Q35895422-60E5EA87-58D0-4D6A-9A20-06212C24AA27

P698

Q35895422-4C04D7E3-B489-4ABF-BC56-90C4FC90A0F3

P932

Q35895422-F3040E98-6290-4EC8-8981-41A983664DBA

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Synbiotics Easing Renal Failur ...... (SYNERGY): A Randomized Trial

@en

P2093

Brett C McWhinney

http://www.w3.org/2001/XMLSchema#string

Cheuk-Chun Szeto

http://www.w3.org/2001/XMLSchema#string

David W Johnson

http://www.w3.org/2001/XMLSchema#string

Elaine M Pascoe

http://www.w3.org/2001/XMLSchema#string

Megan Rossi

http://www.w3.org/2001/XMLSchema#string

P2860

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?

Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD.

SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial

p-Cresol and cardiovascular risk in mild-to-moderate kidney disease

Functional metabolic map of Faecalibacterium prausnitzii, a beneficial human gut microbe.

Chronic kidney disease: global dimension and perspectives.

Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress

Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein.

Bifidobacterium fermented milk and galacto-oligosaccharides lead to improved skin health by decreasing phenols production by gut microbiota.

P304

223-231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.05240515

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Katrina L. Campbell

Josephine M. Forbes

Jacobus Ungerer

P577

2016-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26772193

http://www.w3.org/2001/XMLSchema#string

P932

4741035

http://www.w3.org/2001/XMLSchema#string